Company intelligence / Profile preview
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine
- Ownership
- Private
- Development stage
- Other
Overview
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine was a joint venture formed in 2005 between Hutchison Whampoa/HUTCHMED and Guangzhou Baiyunshan Pharmaceutical Holdings. It specialized in the modernized manufacturing and marketing of traditional Chinese medicine (TCM) products, focusing on OTC drugs for cardiovascular and cerebrovascular diseases, with some pipeline assets in clinical development. It was divested by HUTCHMED in 2021 and acquired by GL Capital Group.
- Therapeutic areas
- Cardiovascular
- Modalities
- Herbal medicineSmall molecule
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine.